Courtesy Luca Nagel, Department of Nuclear Medicine, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, GermanyQuantum computers? While most people have heard that their massively parallel data processing could open up an entirely new dimension of information technology, tangible real-world examples remain scarce. NVision Imaging Technologies in Ulm has been active in the field for years and has now developed a visible and practical innovation in metabolic imaging: real-time MRI. Leading academic institutions have already expressed strong interest.
Tag Archive for: oncology
Cambridge, UK-based Syndex Bio has announced on Monday the introduction of its proprietary mcPCR™ (methyl-copying PCR) platform at the Advances in Genome Biology and Technology (AGBT) meeting in Orlando, Florida, alongside the close of an oversubscribed $15.5 million seed financing round led by ARCH Venture Partners, with participation from +ND Capital, OMX Ventures and Meltwind Advisory LLP.
RocheRoche made a clear statement in 2025. The Basel-based group increased sales by 7% at constant exchange rates to CHF 61.5bn (€67bn) and lifted core operating profit by as much as 13%. For many observers, this represents far more than just a solid set of annual results.
Amgen has agreed to acquire Dark Blue Therapeutics in a deal valued at up to $840 million, as the biopharmaceutical company continues to build out its early-stage oncology pipeline. The specific breakdown of the upfront payment alongside development and regulatory milestones was not disclosed in the press release.
Organoids are reshaping cancer R&D by providing more accurate, patient-relevant models than classical methods. By bridging the gap between preclinical and early clinical stages, they enable patient-centric target validation, drug discovery, and therapeutic development, representing a significant step toward truly precision oncology
freshidea / Adobe StockLyon-based Ventuno Biotech secures fresh backing to accelerate its preclinical pipeline of first-in-class immuno-oncology assets.
Pilatus BiosciencesPilatus Biosciences AG, a Swiss biotechnology company headquartered in Epalinges with operations in the United States and South Korea, has entered into a clinical trial collaboration with Roche AG. As part of the agreement, Roche will provide its PD-L1 immune checkpoint inhibitor atezolizumab for use in a Phase I study evaluating the combination of atezolizumab with Pilatus’s investigational CD36 inhibitor, PLT012, in patients with hepatocellular carcinoma (HCC).
Ryvu Therapeutics zooKrakow-based oncology specialist Ryvu Therapeutics zoo today announced a strategic reorganisation that will extend Ryvu’s cash runway to H2/2026 to focus on accelerating three ongoing RVU120 clinical programmes, and early pipeline small molecule and ADC assets to key data inflection points.
ProBioGenThe Strasbourg-based biotech company Transgene and the Berlin-based CDMO ProBioGen have entered into a licensing agreement to collaboratively advance the development of individualised cancer vaccines.
AstraZenecaA Phase III trial evaluating AstraZeneca and Daiichi Sankyo’s potential “blockbuster” lung cancer drug Dato-DXd showed no significant improvement over standard chemotherapy. Investors reacted quickly: AstraZeneca’s share price dropped 5% following the announcement.